Daiichi Sankyo's Enhertu wins EU approval for adjuvant treatment of early breast cancer
AZN•The EU approved Enhertu for adjuvant treatment of HER2-positive early breast cancer with residual disease after neoadjuvant therapy. In the phase 3 DESTINY-Breast05 trial, it reduced the risk of invasive disease recurrence or death by 53% versus T-DM1, triggering a $75 million milestone payment from AstraZeneca to Daiichi Sankyo.
1. EU approval and trial results
The EU approved Daiichi Sankyo and AstraZeneca's Enhertu as an adjuvant treatment for HER2-positive early breast cancer with residual disease following neoadjuvant therapy. In the phase 3 DESTINY-Breast05 trial, Enhertu reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1. The approval triggers a $75 million milestone payment from AstraZeneca to its partner.
